Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer
Jessica J. Tao(Harvard University), Maurizio Scaltriti(Harvard University), Haley Ellis(Broad Institute), Tony Ng(King's College London), Moshe Elkabets(Ben-Gurion University of the Negev), Natasha Morse(Memorial Sloan Kettering Cancer Center), Ana Bosch(Memorial Sloan Kettering Cancer Center), Anna Bergamaschi, Borivoj Vojnovic(King's College London), Lisa A. Carey(University of North Carolina at Chapel Hill), Nina Radosevic‐Robin(University of Clermont Auvergne), Neil Auricchio(Brigham and Women's Hospital), Paul R. Barber(King's College London), Frédérique Penault‐Llorca(Inserm), Gregory Weitsman(King's College London), Charles M. Perou(University of North Carolina at Chapel Hill), Jason S. Lewis(Memorial Sloan Kettering Cancer Center), Shyamala Maheswaran(Massachusetts General Hospital), Nerissa T. Viola(Wayne State University), Sharat Singh(Mirati Therapeutics (United States)), Nicola Aceto(ETH Zurich), Pau Castel(Memorial Sloan Kettering Cancer Center), Dejan Juric(Massachusetts General Hospital), Phillip Kim(Prometheus Biosciences (United States)), Saswati Hazra(Prometheus Biosciences (United States)), José Baselga(Novartis (Switzerland))
Cited by 166
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k